104 related articles for article (PubMed ID: 38956880)
1. Early determination of potential critical quality attributes of therapeutic antibodies in developability studies through surface plasmon resonance-based relative binding activity assessment.
Wang S; Wang Y; Li Z; Hong Y; Wang Z; Fan J; Wang Q; Ge Y; Zhao X; Cheng G; Chen C; Wu Y; Fu Y
MAbs; 2024; 16(1):2374607. PubMed ID: 38956880
[TBL] [Abstract][Full Text] [Related]
2. A competitive binding-mass spectrometry strategy for high-throughput evaluation of potential critical quality attributes of therapeutic monoclonal antibodies.
Zhang Z; Yan Y; Wang S; Li N
MAbs; 2022; 14(1):2133674. PubMed ID: 36224723
[TBL] [Abstract][Full Text] [Related]
3. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM
MAbs; 2021; 13(1):1980942. PubMed ID: 34850665
[TBL] [Abstract][Full Text] [Related]
4. Engineering an anti-CD52 antibody for enhanced deamidation stability.
Qiu H; Wei R; Jaworski J; Boudanova E; Hughes H; VanPatten S; Lund A; Day J; Zhou Y; McSherry T; Pan CQ; Sendak R
MAbs; 2019 Oct; 11(7):1266-1275. PubMed ID: 31199181
[TBL] [Abstract][Full Text] [Related]
5. High-throughput screening of antibody variants for chemical stability: identification of deamidation-resistant mutants.
DiCara DM; Andersen N; Chan R; Ernst JA; Ayalon G; Lazar GA; Agard NJ; Hilderbrand A; Hötzel I
MAbs; 2018 Oct; 10(7):1073-1083. PubMed ID: 30130444
[TBL] [Abstract][Full Text] [Related]
6. Assessment of chemical modifications of sites in the CDRs of recombinant antibodies: Susceptibility vs. functionality of critical quality attributes.
Haberger M; Bomans K; Diepold K; Hook M; Gassner J; Schlothauer T; Zwick A; Spick C; Kepert JF; Hienz B; Wiedmann M; Beck H; Metzger P; Mølhøj M; Knoblich C; Grauschopf U; Reusch D; Bulau P
MAbs; 2014; 6(2):327-39. PubMed ID: 24441081
[TBL] [Abstract][Full Text] [Related]
7. N+1 Engineering of an Aspartate Isomerization Hotspot in the Complementarity-Determining Region of a Monoclonal Antibody.
Patel CN; Bauer SP; Davies J; Durbin JD; Shiyanova TL; Zhang K; Tang JX
J Pharm Sci; 2016 Feb; 105(2):512-518. PubMed ID: 26869414
[TBL] [Abstract][Full Text] [Related]
8. Charge variants characterization and release assay development for co-formulated antibodies as a combination therapy.
Cao M; De Mel N; Shannon A; Prophet M; Wang C; Xu W; Niu B; Kim J; Albarghouthi M; Liu D; Meinke E; Lin S; Wang X; Wang J
MAbs; 2019 Apr; 11(3):489-499. PubMed ID: 30786796
[TBL] [Abstract][Full Text] [Related]
9. Determining the affinities of high-affinity antibodies using KinExA and surface plasmon resonance.
Erasmus MF; Dovner M; Ferrara F; D'Angelo S; Teixeira AA; Leal-Lopes C; Spector L; Hopkins E; Bradbury ARM
MAbs; 2023; 15(1):2291209. PubMed ID: 38088807
[TBL] [Abstract][Full Text] [Related]
10. Affinity profiling of monoclonal antibody and antibody-drug-conjugate preparations by coupled liquid chromatography-surface plasmon resonance biosensing.
Lakayan D; Haselberg R; Gahoual R; Somsen GW; Kool J
Anal Bioanal Chem; 2018 Dec; 410(30):7837-7848. PubMed ID: 30328504
[TBL] [Abstract][Full Text] [Related]
11. Impact of Tryptophan Oxidation in Complementarity-Determining Regions of Two Monoclonal Antibodies on Structure-Function Characterized by Hydrogen-Deuterium Exchange Mass Spectrometry and Surface Plasmon Resonance.
Hageman T; Wei H; Kuehne P; Fu J; Ludwig R; Tao L; Leone A; Zocher M; Das TK
Pharm Res; 2018 Dec; 36(1):24. PubMed ID: 30536043
[TBL] [Abstract][Full Text] [Related]
12. Anti-peptide antibody screening: selection of high affinity monoclonal reagents by a refined surface plasmon resonance technique.
Pope ME; Soste MV; Eyford BA; Anderson NL; Pearson TW
J Immunol Methods; 2009 Feb; 341(1-2):86-96. PubMed ID: 19041872
[TBL] [Abstract][Full Text] [Related]
13. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs.
Teixeira AAR; D'Angelo S; Erasmus MF; Leal-Lopes C; Ferrara F; Spector LP; Naranjo L; Molina E; Max T; DeAguero A; Perea K; Stewart S; Buonpane RA; Nastri HG; Bradbury ARM
MAbs; 2022; 14(1):2115200. PubMed ID: 36068722
[TBL] [Abstract][Full Text] [Related]
15. Targeted CQA analytical control strategy for commercial antibody products: Replacing ion-exchange chromatography methods for charge heterogeneity with multi-attribute monitoring.
Evans AR; Mulholland J; Lewis MJ; Hu P
MAbs; 2024; 16(1):2341641. PubMed ID: 38652517
[TBL] [Abstract][Full Text] [Related]
16. Using bispecific antibodies in forced degradation studies to analyze the structure-function relationships of symmetrically and asymmetrically modified antibodies.
Evans AR; Capaldi MT; Goparaju G; Colter D; Shi FF; Aubert S; Li LC; Mo J; Lewis MJ; Hu P; Alfonso P; Mehndiratta P
MAbs; 2019; 11(6):1101-1112. PubMed ID: 31161859
[TBL] [Abstract][Full Text] [Related]
17. Determination of concentration and binding affinity of antibody fragments by use of surface plasmon resonance.
Kikuchi Y; Uno S; Nanami M; Yoshimura Y; Iida S; Fukushima N; Tsuchiya M
J Biosci Bioeng; 2005 Sep; 100(3):311-7. PubMed ID: 16243282
[TBL] [Abstract][Full Text] [Related]
18. Label free checkerboard assay to determine overlapping epitopes of Ebola virus VP-40 antibodies using surface plasmon resonance.
Anderson GP; Liu JL; Zabetakis D; Legler PM; Goldman ER
J Immunol Methods; 2017 Mar; 442():42-48. PubMed ID: 28109682
[TBL] [Abstract][Full Text] [Related]
19. Structure, heterogeneity and developability assessment of therapeutic antibodies.
Xu Y; Wang D; Mason B; Rossomando T; Li N; Liu D; Cheung JK; Xu W; Raghava S; Katiyar A; Nowak C; Xiang T; Dong DD; Sun J; Beck A; Liu H
MAbs; 2019; 11(2):239-264. PubMed ID: 30543482
[TBL] [Abstract][Full Text] [Related]
20. Surface Plasmon Resonance kinetic analysis of the interaction between G-quadruplex nucleic acids and an anti-G-quadruplex monoclonal antibody.
Lago S; Nadai M; Rossetto M; Richter SN
Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1276-1282. PubMed ID: 29524541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
